Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies

Journal of Clinical Oncology

Volumn 21, Issue 21, 2003, Pages 3955-3964

  Morgan, Bruno ^a   Thomas, Anne L ^a   Drevs, Joachim ^a   Hennig, Juergen ^a   Buchert, Martin ^a   Jivan, Asvina ^a   Horsfield, Mark A ^a   Mross, Klauss ^a   Ball, Howard A ^a   Lee, Lucy ^a   Mietlowski, William ^a   Fuxius, Stefan ^a   Unger, Clemens ^a   O'Byrne, Ken ^a   Henry, Andrew ^a   Cherryman, Graham R ^a   Laurent, Dirk ^a   Dugan, Margaret ^a   Marmé, Dieter ^a   Steward, William P ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; VASCULOTROPIN RECEPTOR; VATALANIB; ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM; DICHLOROBIS(ETHYLENEDIAMINE)RHODIUM(III); ORGANOMETALLIC COMPOUND; PHTHALAZINE DERIVATIVE; PYRIDINE DERIVATIVE;

ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG PENETRATION; DRUG RESPONSE; HUMAN; LIVER METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; ADULT; AGED; AREA UNDER THE CURVE; BLOOD; COLORECTAL TUMOR; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; LIVER TUMOR; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PREDICTION AND FORECASTING; STANDARD; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOGENESIS INHIBITORS; AREA UNDER CURVE; BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; CONTRAST MEDIA; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOMETALLIC COMPOUNDS; PHTHALAZINES; PREDICTIVE VALUE OF TESTS; PYRIDINES; TREATMENT OUTCOME;

EID: 0347615101     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.08.092     Document Type: Article

References (47)

1. Folkman J: Tumors angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186, 1971
2. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763, 1995
3. Hayes AJ, Li LY, Lippman ME: Science, medicine, and the future: Antivascular therapy - A new approach to cancer treatment. BMJ 318:853-856, 1999
4. Siemeister G, Martiny-Baron G, Marme D: The pivotal role of VEGF in tumors angiogenesis: Molecular facts and therapeutic opportunities. Cancer Metastasis Rev 17:241-248, 1998
5. Ferrara N: Vascular endothelial growth factor. Eur J Cancer 32:2413-2422, 1996
6. Dvorak HF, Brown LF, Detmar M, et al: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039, 1995
7. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumors growth in vivo. Nature 362:841-844, 1993
8. Wood JM, Bold G, Stover D, et al: Pharmacological profile of a novel, potent and orally active inhibitor of VEGF receptor tyrosine kinases. Cancer Res 60:2178-2189, 2000
9. Drevs J, Hofmann I, Hugenschmidt H, et al: Effect of PTK787/ZK 222584, a specific vascular endothelial growth factor (VEGF) - receptor tyrosine kinase, on primary tumors, metastasis, vessel density and blood flow in a murine renal cell carcinoma. Cancer Res 60:4819-4824, 2000
10. Bold G, Altmann KH, Frei J, et al: New anilino-phthalazines as potent and orally well absorbed inhibitors of the Vegf receptor tyrosine kinases useful as antagonists of tumor driven angiogenesis. J Med Chem 4:2310-2323, 2000
11. Brown LF, Berse B, Jackman RW, et al: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53:4727-4735, 1993
12. Drevs J, Mross K, Fuxius S, et al: A phase I dose escalating and pharmacokinetic (PK) study of the VEGF-receptor inhibitor PTK787/ZK 222584 (PTK/ZK) in patients with liver metastasis of advanced cancer. Proc Am Soc Clin Oncol 20:398, 2001 (abstr 398)
13. Thomas A, Morgan B, Rowark G, et al: Phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK 222584 on a twice daily schedule in patients with advanced cancer. Clin Cancer Res 7:48, 2001 (suppl)
14. Yung, WA, Friedman H, Jackson E, et al: A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGFR TK inhibitor in recurrent glioblastoma. Proc Am Soc Clin Oncol 21:315, 2002 (abstr 315)
15. George D, Jonasch E, Hart L, et al: A phase I, dose-escalating and pharmacokinetic (PK) study of the VEGF-receptor inhibitor PTK787/ZK 222584 (PTK/ZK) in patients with advanced renal cell or prostate carcinomas. Clin Cancer Res 7:548, 2001 (suppl)
16. Moertel CG, Hanley JA: The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 38:388-394, 1976
17. James K, Eisenhauer E, Christian M, et al: Measuring response in solid tumors: Unidimensional versus bidimensional measurement. J Natl Cancer Inst 91:523-528, 1999
18. Yuh WT: An exciting and challenging role for advanced contrast MR imaging. J Magn Reson Imaging 10:221-222, 1999
19. Taylor JS, Tofts PS, Port R, et al: MR imaging of tumors microcirculation: Promise for the new millennium. J Magn Reson Imaging 10:903-907, 1999
20. Knopp MV, Weiss E, Sinn HP, et al: Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 10:260-266, 1999
21. Buadu LD, Murakami J, Murayama S, et al: Breast lesions: Correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumors angiogenesis. Radiology 200:639-649, 1996
22. Hawighorst H, Knapstein PG, Weikel W, et al: Angiogenesis of uterine cervical carcinoma: Characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res 57:4777-4786, 1997
23. Hawighorst H, Weikel W, Knapstein PG, et al: Angiogenic activity of cervical carcinoma: Assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 4:2305-2312, 1998
24. Mayr NA, Hawighorst H, Yuh WT, et al: MR microcirculation assessment in cervical cancer: Correlations with histomorphological tumors markers and clinical outcome. J Magn Reson Imaging 10:267-276, 1999
25. Mayr NA, Yuh WT, Zheng J, et al: Prediction of tumors control in patients with cervical cancer: Analysis of combined volume and dynamic enhancement pattern by MR imaging. AJR Am J Roentgenol 170:177-182, 1998
26. Erlemann R, Sciuk J, Bosse A, et al: Response of osteosarcoma and Ewing sarcoma to prcoperative chemotherapy: Assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology 175:791-796, 1990
27. Fletcher BD, Hanna SL, Fairclough DL, et al: Pediatric musculoskeletal tumors: Use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy. Radiology 184:243-248, 1992
28. Reddick WE, Taylor JS, Fletcher BD: Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging 10:277-285, 1999
29. Barentsz JO, Berger-Hartog O, Witjes JA, et al: Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 207:791-797, 1998
30. Pham CD, Roberts TP, van Bruggen N, et al: Magnetic resonance imaging detects suppression of tumors vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 16:225-230, 1998
31. Brasch R, Pham C, Shames D, et al: Assessing tumors angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 7:68-74, 1997
32. Drevs J, Schmidt-Gersbach C, Mross K, et al: Surrogate markers for the assessment of biological activity of the VEGF-receptor inhibitor PTK787/ZK 222584 (PTK/ZK) in two clinical phase I trials. Proc Am Soc Clin Oncol 21:337, 2002 (abstr 337)
33. Biomarkers Definitions Working Group, Bethesda MK: Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89-95, 2001
34. Larsson HB, Fritz-Hansen T, Rostrup E, et al: Myocardial perfusion modeling using MRI. Magn Reson Med 35:716-726, 1996
35. Cullen JH, Horsfield MA, Reek CR, et al: A myocardial perfusion reserve index in humans using first-pass contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol 33:1386-1394, 1999
36. Jivan A, Horsfield MA, Moody AR, et al: Dynamic T1 measurement using snapshot FLASH MRI. J Magn Reson 127:65-72, 1997
37. Haase A, Matthaei D, Bartkowski R, et al: Inversion recovery snapshot FLASH MR imaging. J Comput Assist Tomogr 13:1036-1040, 1989
38. Morgan B, Jivan A, Horsfield MA, et al: Validation of a snapshot FLASH protocol for rapid assessment of contrast enhancement to monitor tumors therapy. Proc Intl Soc Mag Reson Med 8:1036, 2000 (abstr 1036)
39. Fritz-Hansen T, Rostrup E, Larsson HB, et al: Measurement of the arterial concentration of Gd-DTPA using MRI: A step toward quantitative perfusion imaging. Magn Reson Med 36:225-231, 1996
40. Tofts PS, Brix G, Buckley DL, et al: Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging 10:223-232, 1999
41. Su MY, Muhler A, Lao X, et al: Tumors characterization with dynamic contrast-enhanced MRI using MR contrast agents of various molecular weights. Magn Reson Med 39:259-269, 1998
42. Daldrup H, Shames DM, Wendland M, et al: Correlation of dynamic contrast-enhanced MR imaging with histologic tumors grade: Comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol 171:941-949, 1998
43. Larsson HB, Stubgaard M, Sondergaard L, et al: In vivo quantification of the unidirectional influx constant for Gd-DTPA diffusion across the myocardial capillaries with MR imaging. J Magn Reson Imaging 4:433-440, 1994
44. Jain RK, Safabakhsh N, Sckell A, et al: Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumors: Role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 95:10820-10825, 1998
45. Benjamin LE, Golijanin D, Itin A, et al: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159-165, 1999
46. Li KL, Zhu XP, Jayson G, et al: Quantitative dynamic contrast enhanced MRI in tumors: A reproducible technique in the head? A reproducible technique in the breast? Proc Intl Soc Mag Reson Med 8:724, 2000 (abstr 724)
47. Evelhoch JL: Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10:254-259, 1999